Showing results (2161-2170 of 2,317) with videos related to

Sort By:
Pageof 232
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
Breast Cancer Research and Treatment|December 2, 2022
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBinghe Xu, Tao Sun, Yanxia Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC TrialSilvia Novello, Ying Cheng, David Spigel, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2013
Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 chinese cancer patientsYu-Lin Zhu, Guo-Hong Song, Duan-Qi Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
The New England Journal of Medicine|October 4, 2018
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung CancerLuis Paz-Ares, Alexander Luft, David Vicente, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
The Journal of Infectious Diseases|June 6, 2024
Dengue NS1 Antibodies Are Associated With Clearance of Viral Nonstructural Protein-1Michelle Premazzi Papa, Evelyn Mendoza-Torres, Peifang Sun, et al.
BMJ (Clinical Research Ed.)|March 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trialZhi Peng, Yanqiao Zhang, Huiting Xu, et al.
The Lancet. Respiratory Medicine|November 24, 2024
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trialDongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
Pageof 232